The ABPI exists to make the UK the best place in the world to research, develop and use new medicines. We represent companies of all sizes who invest in discovering the medicines of the future.
Our members supply cutting edge treatments that improve and save the lives of millions of people. We work in partnership with Government and the NHS so patients can get new treatments faster and the NHS can plan how much it spends on medicines. Every day, we partner with organisations in the life sciences community and beyond to transform lives across the UK.
1. The review of immunisation cost-effectiveness methodology began following the appraisal by the Joint Committee on Vaccinations and Immunisation (JCVI) of the vaccine for Meningococcal B. During this review, concerns were raised by the JCVI, health professionals, patient groups, industry and many members of the public, that the system used to assess cost-effectiveness may not be appropriate particularly when considering vaccination against severe diseases which disproportionately affected the youngest members of the population. In October 2013 JCVI suggested that a Working Group on Cost-effectiveness be established to examine the question of how the impact of vaccination programmes to prevent rare diseases of high severity could best be assessed and whether there were aspects of cost-effectiveness in relation specifically to children that should be considered.
2. The petition on access to the Meningococcal B vaccine was the third largest petition ever submitted to the House of Commons petitions committee.